Centro de Acufenos Buenos Aires - Oto 313 The purpose of this study is to evaluate the safety, tolerability, plasma pharmacokinetics (PK), and exploratory efficacy of OTO-313 administered as an intratympanic injection
TFI responder analysis (part B; evaluable set). Responders with TFI... | Download Scientific Diagram
![BREAKING: Otonomy Completes Phase 2 Clinical Trial of OTO-313 for Tinnitus... - Tinnitus Treatment Report BREAKING: Otonomy Completes Phase 2 Clinical Trial of OTO-313 for Tinnitus... - Tinnitus Treatment Report](https://www.tinnitustreatmentreport.com/wp-content/uploads/oto-313-phase-2-completed-july-2022.png)
BREAKING: Otonomy Completes Phase 2 Clinical Trial of OTO-313 for Tinnitus... - Tinnitus Treatment Report
![SY Investing on X: "$OTIC (+15% PM) Otonomy reported positive topline data data from the Phase 1/2 trial of OTO-313 in patients with tinnitus. 43% of OTO-313 patients were responders at both SY Investing on X: "$OTIC (+15% PM) Otonomy reported positive topline data data from the Phase 1/2 trial of OTO-313 in patients with tinnitus. 43% of OTO-313 patients were responders at both](https://pbs.twimg.com/media/EcUKvlLUYAEBFeM.jpg)
SY Investing on X: "$OTIC (+15% PM) Otonomy reported positive topline data data from the Phase 1/2 trial of OTO-313 in patients with tinnitus. 43% of OTO-313 patients were responders at both
![Otonomy Now Recruiting Participants for Phase 2 Study of OTO-313 in Tinnitus [Update: New Locations Added] - Tinnitus Treatment Report Otonomy Now Recruiting Participants for Phase 2 Study of OTO-313 in Tinnitus [Update: New Locations Added] - Tinnitus Treatment Report](https://www.tinnitustreatmentreport.com/wp-content/uploads/oto-313-phase-2-article.png)
Otonomy Now Recruiting Participants for Phase 2 Study of OTO-313 in Tinnitus [Update: New Locations Added] - Tinnitus Treatment Report
![PDF) Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study PDF) Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study](https://i1.rgstatic.net/publication/355235647_Intratympanic_Administration_of_OTO-313_Reduces_Tinnitus_in_Patients_With_Moderate_to_Severe_Persistent_Tinnitus_A_Phase_12_Study/links/6194002b3068c54fa5f14d32/largepreview.png)
PDF) Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study
Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study
OTO-313 is a new pharmaceutical research drug aimed at finding a cure for tinnitus. Know more about the latest update about this new research drug! Watch the video here: https://bit.ly/PTACFT21 | OTO-313
![PDF) Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study PDF) Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study](https://www.researchgate.net/publication/355235647/figure/fig2/AS:1093099203895296@1637626567142/TFI-responder-analysis-part-B-evaluable-set-Responders-with-TFI-improvement-at-both_Q320.jpg)
PDF) Intratympanic Administration of OTO-313 Reduces Tinnitus in Patients With Moderate to Severe, Persistent Tinnitus: A Phase 1/2 Study
![A randomized, double-blind, placebo-controlled phase 2 study of intratympanic OTO-313 in patients with moderate to severe subjective tinnitus | European Archives of Oto-Rhino-Laryngology A randomized, double-blind, placebo-controlled phase 2 study of intratympanic OTO-313 in patients with moderate to severe subjective tinnitus | European Archives of Oto-Rhino-Laryngology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00405-023-08047-0/MediaObjects/405_2023_8047_Fig3_HTML.png)
A randomized, double-blind, placebo-controlled phase 2 study of intratympanic OTO-313 in patients with moderate to severe subjective tinnitus | European Archives of Oto-Rhino-Laryngology
![SY Investing on X: "$OTIC (+15% PM) Otonomy reported positive topline data data from the Phase 1/2 trial of OTO-313 in patients with tinnitus. 43% of OTO-313 patients were responders at both SY Investing on X: "$OTIC (+15% PM) Otonomy reported positive topline data data from the Phase 1/2 trial of OTO-313 in patients with tinnitus. 43% of OTO-313 patients were responders at both](https://pbs.twimg.com/media/EcUKvlTU8AArlaC.jpg)